MA28531B1 - Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4 - Google Patents

Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4

Info

Publication number
MA28531B1
MA28531B1 MA29385A MA29385A MA28531B1 MA 28531 B1 MA28531 B1 MA 28531B1 MA 29385 A MA29385 A MA 29385A MA 29385 A MA29385 A MA 29385A MA 28531 B1 MA28531 B1 MA 28531B1
Authority
MA
Morocco
Prior art keywords
pdea4
pyrazolo
pyridine
inhibitor
composition
Prior art date
Application number
MA29385A
Other languages
English (en)
Inventor
Siegfried Benjamin Christensen Iv
Caroline Mary Cook
Christopher David Edlin
Martin Redpath Johnson
Paul Spencer Jones
Mika Kristian Lindvall
Amyn Pyarali Sayani
Naimisha Trivedi
Lionel Trottet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0405893A external-priority patent/GB0405893D0/en
Priority claimed from GB0505214A external-priority patent/GB0505214D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28531B1 publication Critical patent/MA28531B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MA29385A 2004-03-16 2006-10-13 Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4 MA28531B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0405893A GB0405893D0 (en) 2004-03-16 2004-03-16 Compounds
GB0505214A GB0505214D0 (en) 2005-03-14 2005-03-14 Compounds

Publications (1)

Publication Number Publication Date
MA28531B1 true MA28531B1 (fr) 2007-04-03

Family

ID=34962723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29385A MA28531B1 (fr) 2004-03-16 2006-10-13 Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4

Country Status (15)

Country Link
US (2) US20080275078A1 (fr)
EP (2) EP1740590A1 (fr)
JP (2) JP2007529486A (fr)
KR (1) KR20060130744A (fr)
AR (1) AR048175A1 (fr)
AU (1) AU2005223351A1 (fr)
BR (1) BRPI0508843A (fr)
CA (1) CA2559629A1 (fr)
IL (1) IL178011A0 (fr)
MA (1) MA28531B1 (fr)
NO (1) NO20064450L (fr)
PE (1) PE20060078A1 (fr)
RU (1) RU2378274C2 (fr)
TW (1) TW200602051A (fr)
WO (2) WO2005090354A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
CA2557004A1 (fr) * 2003-12-19 2005-06-30 Glaxo Group Limited Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase
WO2005090354A1 (fr) 2004-03-16 2005-09-29 Glaxo Group Limited Composes de pyrazolo[3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de pde4
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
AR061571A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
PE20091552A1 (es) 2008-02-06 2009-10-25 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
WO2009100169A1 (fr) * 2008-02-06 2009-08-13 Glaxo Group Limited Pharmacophores duals, antagonistes des récepteurs muscariniques et inhibiteurs de l'activité pde4
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
PE20091563A1 (es) 2008-02-06 2009-11-05 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
GB0806900D0 (en) * 2008-04-16 2008-05-21 Dow Corning Fabric care emulsions
WO2009147187A1 (fr) 2008-06-05 2009-12-10 Glaxo Group Limited Dérivés de 4-carboxamide indazole utiles en tant qu'inhibiteurs de p13 kinases
US8470835B2 (en) 2009-01-13 2013-06-25 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
WO2010102958A1 (fr) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles en tant qu'inhibiteurs des p13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2010106016A1 (fr) 2009-03-17 2010-09-23 Glaxo Group Limited Dérivés de pyrimidine utilisés comme inhibiteurs de ltk
ES2404156T3 (es) * 2009-04-13 2013-05-24 Vanangamudi Subramaniam SULUR Una crema medicinal con ácido fusídico hecha utilizando fusidato de sodio e incorporando un biopolímero y el proceso para hacerla
ME02900B (fr) 2009-04-30 2018-04-20 Glaxo Group Ltd Nouveaux composés
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
EP2507226A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Nouveaux composés
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
WO2011110575A1 (fr) 2010-03-11 2011-09-15 Glaxo Group Limited Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
ES2602972T3 (es) 2010-09-08 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe
PT2614058E (pt) 2010-09-08 2015-10-27 Glaxosmithkline Ip Dev Ltd Polimorfos e sais de n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4- morfolinil]metil}-1,3-oxazol-2-il)-1h-indazol-6-il]-2- (metiloxi)-3-piridinil]metanossulfonamida
WO2012035055A1 (fr) 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
KR102142162B1 (ko) 2012-08-27 2020-09-14 에이비 엘렉트로룩스 로봇 위치 선정 시스템
KR102118769B1 (ko) 2013-04-15 2020-06-03 에이비 엘렉트로룩스 로봇 진공 청소기
WO2014169944A1 (fr) 2013-04-15 2014-10-23 Aktiebolaget Electrolux Dispositif de nettoyage sous vide robotisé avec brosse latérale saillante
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
EP3057587A1 (fr) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
JP6475707B2 (ja) 2013-10-17 2019-02-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
ES2656664T3 (es) 2013-12-19 2018-02-28 Aktiebolaget Electrolux Dispositivo robótico de limpieza con función de registro del perímetro
JP6494118B2 (ja) 2013-12-19 2019-04-03 アクチエボラゲット エレクトロルックス 障害物の乗り上げの検出に伴うロボット掃除機の制御方法、並びに、当該方法を有するロボット掃除機、プログラム、及びコンピュータ製品
EP3082541B1 (fr) 2013-12-19 2018-04-04 Aktiebolaget Electrolux Contrôle de la vitesse des brosses latérales en rotation
CN105793790B (zh) 2013-12-19 2022-03-04 伊莱克斯公司 优先化清洁区域
CN105792721B (zh) 2013-12-19 2020-07-21 伊莱克斯公司 以螺旋样式移动的带侧刷的机器人真空吸尘器
CN105813526B (zh) 2013-12-19 2021-08-24 伊莱克斯公司 机器人清扫装置以及用于地标识别的方法
CN105849660B (zh) 2013-12-19 2020-05-08 伊莱克斯公司 机器人清扫装置
KR102116595B1 (ko) 2013-12-20 2020-06-05 에이비 엘렉트로룩스 먼지통
PE20170185A1 (es) 2014-05-12 2017-04-01 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas para tratar enfermedades infecciosas
ES2681802T3 (es) 2014-07-10 2018-09-17 Aktiebolaget Electrolux Método para detectar un error de medición en un dispositivo de limpieza robotizado
EP3190938A1 (fr) 2014-09-08 2017-07-19 Aktiebolaget Electrolux Aspirateur robotisé
JP6443897B2 (ja) 2014-09-08 2018-12-26 アクチエボラゲット エレクトロルックス ロボット真空掃除機
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
US10877484B2 (en) 2014-12-10 2020-12-29 Aktiebolaget Electrolux Using laser sensor for floor type detection
EP3229983B1 (fr) 2014-12-12 2019-02-20 Aktiebolaget Electrolux Brosse latérale et appareil de nettoyage robotique
CN106998984B (zh) 2014-12-16 2021-07-27 伊莱克斯公司 用于机器人清洁设备的清洁方法
JP6879478B2 (ja) 2014-12-16 2021-06-02 アクチエボラゲット エレクトロルックス ロボット掃除機のための経験ベースロードマップ
WO2016165772A1 (fr) 2015-04-17 2016-10-20 Aktiebolaget Electrolux Dispositif de nettoyage robotique et procédé de commande de dispositif de nettoyage robotique
EP3344104B1 (fr) 2015-09-03 2020-12-30 Aktiebolaget Electrolux Système de dispositifs de nettoyage robotisés
SI3359541T1 (sl) * 2015-10-09 2021-01-29 Abbvie Overseas S.A R.L. N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3430424B1 (fr) 2016-03-15 2021-07-21 Aktiebolaget Electrolux Dispositif de nettoyage robotique et procédé au niveau du dispositif de nettoyage robotique pour effectuer une détection de falaise
EP3454707B1 (fr) 2016-05-11 2020-07-08 Aktiebolaget Electrolux Robot de nettoyage
EP3497100A1 (fr) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Composés chimiques
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
KR20220025250A (ko) 2017-06-02 2022-03-03 에이비 엘렉트로룩스 로봇 청소 장치 전방의 표면의 레벨차를 검출하는 방법
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP6989210B2 (ja) 2017-09-26 2022-01-05 アクチエボラゲット エレクトロルックス ロボット清掃デバイスの移動の制御
KR102034538B1 (ko) * 2017-11-28 2019-10-21 주식회사한국파마 Jak 저해제 화합물, 및 이의 제조방법
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
BE787249A (fr) 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3856799A (en) 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
CA1003419A (en) 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
US3840546A (en) 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3979399A (en) 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) * 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US4364948A (en) 1981-09-28 1982-12-21 Ici Americas Inc. Pyrazolo[3,4-b]pyridine compounds
GB8425104D0 (en) 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
DE60026155T2 (de) 1999-09-30 2006-08-10 Neurogen Corp., Branford Einige alkylendiamin-substituierte heterocyclen
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
MXPA03007134A (es) 2001-02-08 2004-10-15 Memory Pharm Corp Trifluorometilpurinas como inhibidores de fosfodiesterasa 4.
US6677365B2 (en) 2001-04-03 2004-01-13 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
US20050043319A1 (en) 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
FR2828693B1 (fr) 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
CN100387598C (zh) * 2002-09-16 2008-05-14 葛兰素集团有限公司 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
US7117650B2 (en) * 2002-12-09 2006-10-10 Forrest Dockery Hanger system
CA2557004A1 (fr) * 2003-12-19 2005-06-30 Glaxo Group Limited Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
WO2005090354A1 (fr) * 2004-03-16 2005-09-29 Glaxo Group Limited Composes de pyrazolo[3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de pde4
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
IL178011A0 (en) 2006-12-31
AU2005223351A1 (en) 2005-09-29
PE20060078A1 (es) 2006-03-10
NO20064450L (no) 2006-11-14
WO2005090352A1 (fr) 2005-09-29
KR20060130744A (ko) 2006-12-19
WO2005090354A1 (fr) 2005-09-29
EP1740590A1 (fr) 2007-01-10
AR048175A1 (es) 2006-04-05
US7709497B2 (en) 2010-05-04
RU2378274C2 (ru) 2010-01-10
EP1735314A1 (fr) 2006-12-27
JP2007529486A (ja) 2007-10-25
JP2007529464A (ja) 2007-10-25
TW200602051A (en) 2006-01-16
US20080275078A1 (en) 2008-11-06
BRPI0508843A (pt) 2007-08-28
US20070280971A1 (en) 2007-12-06
RU2006132684A (ru) 2008-04-27
CA2559629A1 (fr) 2005-09-29

Similar Documents

Publication Publication Date Title
MA28531B1 (fr) Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4
HK1097269A1 (en) Tricyclic compounds and their use as mglur1 antagonists
NO20071364L (no) 6H-[l] benzopyrano[4,3-b]-kinoliner og deres anvendelse som østrogenmidler
IS7662A (is) Ný þríhringlaga spírópíperídín eða spírópýrrólídín
DK1381363T3 (da) Imidazo[1,2-a]pyridinderivater som mGluR5-antagonister
IL179149A0 (en) Therapeutic compounds: pyridine as scaffold
DK1611131T3 (da) Pyrazolopyridin-derivater
HK1084384A1 (en) Pyrazolo [3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
DK3536344T3 (da) Superfin formoterolformulering
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
DK1814880T3 (da) Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed
ATE396724T1 (de) 1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer
IL178461A0 (en) Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
ATE382261T1 (de) Flüssige formulierung
GB0319874D0 (en) Novel formulation
NO20055518D0 (no) 5-hydroksyindoler med N-oksidgrupper, anvendelse derav som fosfodiesterase 4-inhibitor
EP1786433A4 (fr) Derives de betulinol utilises en tant qu'agents anti-vih
AU2003268075A1 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
AU2002251140A1 (en) Chemical derivatives and their use as anti-telomerase agent
CY2011018I1 (el) Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος
DE60208403D1 (de) Reaktive Polyurethanzusammensetzung
PL377902A1 (pl) Nowe zastosowanie kompleksu fosfor-azot-metal
SG150544A1 (en) Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivatives, their manufacture and use as pharmaceutical agents
AU2002229859A1 (en) Chemical derivatives and their use as anti-telomerase agent